Know Cancer

forgot password

Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders

Phase 1/Phase 2
21 Years
Open (Enrolling)
Leukemia, Myelodysplastic/Myeloproliferative Neoplasms

Thank you

Trial Information

Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders


- Determine the toxic effects of tipifarnib in adult patients with myeloproliferative

- Determine hematological responses, including changes in WBC count and erythroid
responses, in this patient population treated with this drug.

- Determine the cytogenetic response in bone marrow of patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to prior substantive
treatment (yes vs no).

Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 4 weeks
for a maximum of 4 courses in the absence of unacceptable toxicity or disease progression.
Patients with continued hematologic response after completion of the fourth course may
receive additional courses at the discretion of the investigator.

PROJECTED ACCRUAL: A total of 25 patients (12-13 per stratum) will be accrued for this study
within 25 months.

Inclusion Criteria


- Diagnosis of chronic myelogenous leukemia (CML)

- Philadelphia chromosome (Ph) positive OR

- BCR-ABL positive by polymerase chain reaction

- Must meet 1 of the following 2 conditions:

- Chronic phase

- Persistent or progressive disease on maximum tolerated interferon or
imatinib mesylate, as evidenced by increasing WBC count, peripheral
blood myeloid immaturity, progressive anemia, and/or persistence or
relapse of abnormal cytogenetics and/or molecular findings

- Interferon or imatinib mesylate intolerant

- Accelerated phase

- Persistent or progressive disease on imatinib mesylate

- Patients who have not received interferon or imatinib mesylate due to
allergy or refusal are eligible OR

- Diagnosis of chronic myelomonocytic leukemia

- Proliferative type (WBC at least 12,000/mm3)

- Less than 5% blasts in peripheral blood and no more than 20% blasts in bone
marrow OR

- Diagnosis of undifferentiated myeloproliferative disorder OR

- Diagnosis of atypical CML (Ph negative)

- No blast crisis phase of CML, atypical CML, or undifferentiated myeloproliferative

- No more than 20% blasts in peripheral blood or bone marrow

- Diagnosed more than 3 months before study entry



- 21 and over

Performance status:

- ECOG 0-2

Life expectancy:

- More than 4 months


- See Disease Characteristics

- No requirement for platelet transfusion

- No thrombocytopenia-related bleeding


- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- AST/ALT no greater than 2 times ULN


- Creatinine no greater than 2.0 mg/dL


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Capable of swallowing capsules

- No other concurrent severe disease that would preclude study compliance

- No septicemia or other severe infection

- No iron deficiency

- If marrow aspirate not available, transferrin saturation at least 20% and
ferritin greater than 50 ng/mL

- No other contributing causes of anemia (e.g., autoimmune or hereditary hemolytic
disorders, gastrointestinal blood loss, B12 or folate deficiency, or hypothyroidism)


Biologic therapy:

- See Disease Characteristics

- At least 4 weeks since prior interferon

- At least 4 weeks since prior hematopoietic growth factors

- No prior allogeneic bone marrow transplantation


- At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin or
nitrosoureas) except for hydroxyurea which may be used to manage elevated cell counts
through the beginning of the second course of study therapy

Endocrine therapy:

- No concurrent androgens

- No concurrent corticosteroids (e.g., greater than 10 mg/day prednisone or equivalent
steroid dosage) except as premedication for transfusions


- Not specified


- Not specified


- No other concurrent standard or investigational cytotoxic agents

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Peter L. Greenberg, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Stanford University


United States: Federal Government

Study ID:




Start Date:

June 2000

Completion Date:

Related Keywords:

  • Leukemia
  • Myelodysplastic/Myeloproliferative Neoplasms
  • relapsing chronic myelogenous leukemia
  • chronic phase chronic myelogenous leukemia
  • accelerated phase chronic myelogenous leukemia
  • chronic myelogenous leukemia, BCR-ABL1 positive
  • Philadelphia chromosome negative chronic myelogenous leukemia
  • chronic myelomonocytic leukemia
  • atypical chronic myeloid leukemia, BCR-ABL1 negative
  • myelodysplastic/myeloproliferative neoplasm, unclassifiable
  • Neoplasms
  • Leukemia
  • Myeloproliferative Disorders
  • Myelodysplastic-Myeloproliferative Diseases



Veterans Affairs Medical Center - Palo Alto Palo Alto, California  94304
Stanford Cancer Center at Stanford University Medical Center Stanford, California  94305
James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York  14642